What happens when you stop a GLP-1 like Ozempic or Mounjaro?
Weight regain, blood sugar, lower doses, the lifelong cost in ₹, and how to stop safely.
Most people regain much of the lost weight within a year of stopping a GLP-1 medicine such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro). Blood sugar and blood pressure tend to rise again too. Stopping can still be the right choice. Plan it with your doctor, especially if you have diabetes.
Key facts
- Weight after stopping
- About two-thirds of the loss came back within a year in the main semaglutide trial1
- How fast
- About 0.8 kg a month after semaglutide or tirzepatide, on average5
- Lower dose instead
- Tested for tirzepatide only; kept most, not all, of the loss10
- Pregnancy plans
- Stop semaglutide at least 2 months before trying, says the Wegovy label13
On this page
- What happens to your weight when you stop?
- What happens to blood sugar, blood pressure and cholesterol?
- Why does the weight come back?
- Can you take a lower dose, or taper off?
- What helps keep weight off?
- What does staying on it cost over years?
- When is stopping the right call?
- How do you stop safely?
- What if you miss doses or can't get supply?
- Questions people ask
What happens to your weight when you stop?
In trials, most people regained much of the weight they had lost within a year of stopping. On average, they did not go all the way back to where they started.
The clearest test is a one-year follow-up of the main semaglutide trial (the STEP 1 extension). It followed 327 people for a year after treatment stopped: 228 had been on semaglutide 2.4 mg and the rest on a dummy injection.1
327 people, followed for a year after treatment ended.1 For someone who started at 90 kg:
So about two-thirds of the lost weight came back. For a 90 kg person, that means losing about 16 kg, then regaining about 10 kg.1 About half the people (48%) were still at least 5% lighter than at the start.1
Weight change before and after stopping semaglutide (STEP 1)
Average change from starting weight. Lines join the 3 measured points; the real path between them was curved. Source: STEP 1 extension.1
Two more trials tested this differently. Everyone took the medicine first. Then, at random, some carried on and the rest were switched to a dummy injection without knowing. So the gap between the two groups shows what stopping does:
Everyone took it for 20 weeks, then half switched to a dummy injection for 48 weeks.2 For someone who started at 90 kg:
Everyone took it for 36 weeks, then half switched to a dummy injection for 52 weeks.3 For someone who started at 90 kg:
The kg figures are our arithmetic for one example person starting at 90 kg, using each trial's average percentages; real people varied a lot. In both trials about half the lost weight came back after switching. The trials also report regain of 6.9% (STEP 4) and 14.0% (SURMOUNT-4), but those are measured from the lower weight at the switch, so they look different.2,3
Two 2026 reviews pooled many studies. A BMJ review of 37 studies (9,341 people) found weight came back at about 0.8 kg a month after semaglutide or tirzepatide.5 It projected a return to starting weight in about 1.5 years. That is an estimate: no study of these two drugs followed people for more than a year.5
A second review estimated that 60% of the lost weight returns in the first year. It predicted regain would level off at about 75%, not 100%.6 So the two reviews disagree: one projects a full return to starting weight, the other a partial one.5,6 These are averages. In one tirzepatide analysis, 1 in 6 people regained less than a quarter of what they lost.4
What happens to blood sugar, blood pressure and cholesterol?
They tend to drift back towards where they were before treatment. The more weight comes back, the more they rise.
In STEP 1, blood pressure was back at its starting level a year after stopping. Average blood sugar (HbA1c, a 3-month sugar test) and cholesterol also rose again.1
In the tirzepatide trial above (SURMOUNT-4), people who regained the most saw the biggest rises. Top (systolic) blood pressure went up by 7 to 10 points, depending on how much weight came back.4 People who kept most of the weight off kept some benefits, such as lower blood fats (triglycerides).4
The BMJ review projected that all these heart and sugar markers would be back at their starting levels within about 1.4 years.5
Why does the weight come back?
The medicine was holding your appetite down. When it wears off, hunger returns, and your body also pushes to regain lost weight.
Half of each semaglutide dose is still in the body after about a week. It stays in the blood for about 5 to 7 weeks after the last injection.13 As it goes, the feeling of fullness it gave goes too.
Losing weight by any route changes your hunger hormones. In one study of dieting, these changes and stronger hunger were still there a year later.8 The body acts as if it wants the weight back.
This is why experts now call obesity a long-term (chronic) condition, like high blood pressure. The WHO calls it "a chronic, relapsing disease requiring lifelong care".9 The STEP 1 authors said their results suggest ongoing treatment is needed to keep the benefits.1
Regain is not a personal failure. The BMJ review found weight came back faster after medicines than after diet programmes alone, whatever the amount first lost.5
Can you take a lower dose, or taper off?
One good trial says a lower tirzepatide dose keeps most of the weight off. For semaglutide, and for tapering to zero, the evidence is thin.
One trial (SURMOUNT-MAINTAIN) took 378 US adults who had lost weight on tirzepatide 10 or 15 mg. They were split into 3 groups for a year: full dose, 5 mg, or a dummy injection.10
378 adults.10 Everyone first lost weight on tirzepatide. Then they were split into three groups for a year: kept the full dose, dropped to a low 5 mg dose, or switched to a dummy injection. For someone who started at 90 kg:
Most people in this trial were white women.10 So results may differ for Indian men and women. Eli Lilly, which makes tirzepatide, paid for it.10 Staying on a medicine also means staying with its side effects. In the semaglutide trial above (STEP 4), 42% of people who continued semaglutide had stomach side effects, vs 26% on a dummy injection.2
For semaglutide, no finished trial has tested a lower maintenance dose or a slow taper. The first randomised taper trial, in China, had not started recruiting as of October 2026.11 In real life, many people already use lower doses. In one Danish GP practice, 40% of people still on semaglutide after a year took 1 mg or less.11
The WHO's 2025 guideline names "maintenance and discontinuation" as areas where long-term data are limited.9 So a taper plan is your doctor's judgement, not a proven method.
- Common: feeling sick, vomiting, diarrhoea and constipation, mostly when the dose goes up.
- Rare but serious: inflammation of the pancreas (pancreatitis) and gallbladder problems.
- Vomiting or diarrhoea can dry you out (dehydration) and harm the kidneys.
- Ruled out by the US labels for people with a personal or family history of a rare thyroid cancer (MTC) or MEN2; tell your doctor if this applies.
- Not for use in pregnancy.
What helps keep weight off?
Keeping up exercise and support with eating and habits help most. Nothing yet fully replaces the medicine.
A Danish trial gave 195 people who had just lost weight a year of supervised exercise, a GLP-1 medicine (liraglutide), both, or neither. Then all treatment stopped, and 109 of them were weighed again a year later.12
- Medicine plus exercise, against the medicine alone: about 2.5 kg less regain. That difference was small enough that it could have been chance.12
- Exercise alone, against the medicine alone: the medicine-only group regained about 6 kg more.12
So exercise during treatment looks helpful, but this one small trial can't prove how much it adds once you stop the medicine.
That exercise trial used liraglutide, an older daily GLP-1, and followed 109 people.12 Protein and strength training to protect muscle are covered in Guide 8: Life on a GLP-1.
What does staying on it cost over years?
If you need it long term, the cost is long term too. Using MRPs checked on 5 Oct 2026, 5 years costs from about ₹1.2 lakh to about ₹13.4 lakh, depending on the medicine and dose.
These are examples, using prices checked on 5 Oct 2026, not a price list. A pack holds 4 weekly doses, so a year is 13 packs. Pharmacies may sell below MRP, but not above it:
Medicine only. Doctor visits, blood tests and needles are extra.
How we worked out these prices
Prices are MRPs (maximum retail price, printed on the pack). Each comes from the latest maker or news report we found, or from two pharmacy listings that agree, checked 5 Oct 2026. Our arithmetic: price × 13 packs a year (52 weekly doses).
Generic prices are the makers' launch prices from March 2026. The pen starting range runs from Alkem's pen of four doses at ₹1,800 to Dr Reddy's at ₹4,200.25,20 Vials are priced separately: Natco's multi-dose vials start at ₹1,290 a month for lower strengths, up to about ₹1,750 for the top strength.21 A July 2026 report gave an overall span of ₹1,290 to ₹8,000.17 The generic top-dose range runs from Dr Reddy's 4 mg pen (four 1 mg doses, for diabetes) to Sun Pharma's 2.4 mg pen (for weight).20,19 Prices change often and may fall as more generics arrive.
Tirzepatide figures are MRPs as listed by two pharmacies in October 2026.22 They are Lilly's August 2025 launch MRPs (₹17,500 and ₹22,000) less the GST (goods and services tax) cut on medicines from 12% to 5% on 22 September 2025. The National Pharmaceutical Pricing Authority (NPPA), India's drug price regulator, told makers to pass that cut on.18,23,24
In one Danish GP practice, 38% had stopped semaglutide within a year, for all reasons.11 Before you start, ask whether you could afford it for years, not months. Guide 6 covers medicines and prices in India.
When is stopping the right call?
Stopping is a reasonable choice in several situations. A medicine that harms you, isn't working, or can't be paid for is not worth staying on. These are the common reasons.
- Side effects you can't live with, or a serious one such as pancreatitis. Guide 5 lists the warning signs.
- Planning a pregnancy. The Wegovy label says stop semaglutide at least 2 months before trying, because it stays in the body a long time.13 It also says stop if you become pregnant.13 The tirzepatide label warns it may harm an unborn baby.14
- An operation or sedation. These medicines slow the stomach. Rarely, people have breathed in stomach contents during anaesthesia.13 The labels say to tell your surgeon you take one. They say there isn't enough data to know if pausing it helps.13,14
- It isn't working. NICE, the UK health body, says to consider stopping semaglutide if you've lost less than 5% of your weight after 6 months.15
- Cost, if paying for it is straining your family.
- It was never the right medicine for you, for example taken for a few kilos before an event, or without a proper prescription. See Guide 4.
How do you stop safely?
With your doctor, and with a plan for what comes next. Your weight, blood sugar and blood pressure will need watching for months.
Our summary of the evidence on this page, not a clinical protocol.
If you have diabetes, stopping can push your HbA1c up.7 Your doctor may need to add or change another sugar medicine. Don't just stop and wait to see.
Keep the habits you built: regular exercise and the eating patterns that worked. They give you the best chance of holding on to some of the loss.12
What if you miss doses or can't get supply?
A short gap is usually fine. After a longer gap, the label advice is to restart at a lower dose and build up again.
Semaglutide (Wegovy label): take a missed dose within 5 days of the missed dose, that is, as long as your next dose is more than 2 days away. After that, skip it and take the next one on your usual day. If you've missed 2 or more weekly doses in a row, the label restarts you at a lower dose.13
Tirzepatide (Mounjaro label): take a missed dose within 4 days of the missed dose. After that, skip it and take the next one on your usual day.14 The label gives no rule for restarting after a long gap. Ask your doctor what dose to restart on.
Questions people ask
Will all the weight come back if I stop?
Not always all of it. In the main semaglutide trial (STEP 1), people regained about two-thirds of the lost weight in the year after stopping, and ended 5.6% below their starting weight on average.1 Results vary a lot between people.4
Can I stop and start again later?
Many people do, but plan it with your doctor. After 2 or more missed weekly doses, the Wegovy label says to restart at a lower dose and build up again.13
Is it safe to just stop suddenly?
In the trials, people stopped all at once. What followed was a slow return of weight, blood sugar and blood pressure.1,5 If you have diabetes, you need a sugar plan first.
Can I take a lower dose instead of stopping?
For tirzepatide, one trial (SURMOUNT-MAINTAIN) found a 5 mg dose kept most of the loss, though less than the full dose.10 For semaglutide, there's no finished trial yet.11
How long before pregnancy should I stop?
At least 2 months for semaglutide, says the Wegovy label.13 The tirzepatide label gives no set gap, so plan this with your doctor.14
Before you move on
- Most people regain much of the weight within a year of stopping.
- Blood sugar and blood pressure tend to rise again too.
- A lower dose is tested for tirzepatide only; tapering is unproven.
- Keeping up exercise and good habits gives you the best chance of holding on to some of the loss.
- Long-term use can cost lakhs of rupees over 5 years.
- Stop with your doctor; if diabetic, have a sugar plan first.
You've finished the 9 guides
Pick the path that fits you. Each one points to the parts that matter most for your situation.
Sources
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24(8):1553–64. doi:10.1111/dom.14725
- Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 2021;325(14):1414–25. doi:10.1001/jama.2021.3224
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA, 2024;331(1):38–48. doi:10.1001/jama.2023.24945
- Horn DB et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal: a post hoc analysis of SURMOUNT-4. JAMA Internal Medicine, 2026;186(2):157–67. doi:10.1001/jamainternmed.2025.6112
- West S et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, 7 January 2026. doi:10.1136/bmj-2025-085304
- Budini B et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine, 2026;93:103796. doi:10.1016/j.eclinm.2026.103796
- Tzang CC et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine, 2025. doi:10.1016/j.eclinm.2025.103680
- Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. NEJM, 2011;365:1597–604. doi:10.1056/NEJMoa1105816 (a diet study, not a GLP-1 study)
- Celletti F, Farrar J, De Regil L. World Health Organization guideline on the use and indications of GLP-1 therapies for the treatment of obesity in adults (December 2025). JAMA, 2026. doi:10.1001/jama.2025.24288
- Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). The Lancet, 2026. doi:10.1016/S0140-6736(26)00656-2. Funded by Eli Lilly.
- Skandov MD et al. Real-world use of semaglutide for weight management: dose titration, discontinuation patterns and weight changes. Diabetes, Obesity and Metabolism, 2026. doi:10.1111/dom.71092; and ClinicalTrials.gov NCT07783854 (semaglutide dose-tapering trial, not yet recruiting, checked 5 Oct 2026).
- Jensen SBK et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment. eClinicalMedicine, 2024;69:102475. doi:10.1016/j.eclinm.2024.102475
- Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised June 2026: sections 2.4 (missed doses), 5.10 (anaesthesia), 8.3 (pregnancy planning), 12.3 (half-life). PDF
- Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised August 2026: missed doses, 5.9 (anaesthesia), 8.1 and 8.3 (pregnancy, oral contraceptives). PDF
- NICE. Semaglutide for managing overweight and obesity (TA875), recommendation 1.2. Declared interests: some invited clinical experts declare fees or grants from Novo Nordisk and Eli Lilly (NICE's own register of interests for this appraisal). Link
- Medical Dialogues. Emcure Pharma cuts Poviztra price by 55%, starting dose now Rs 3,999 per month (2.4 mg: ₹8,999). 4 April 2026. Link
- Medical Dialogues. Recalls by Dr Reddy's, Torrent put spotlight on quality standards in India's semaglutide market. 10 July 2026. Link
- Business Standard (citing Reuters). Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity (one-month supply: 5 mg ₹17,500; 7.5 and 10 mg ₹22,000). 13 August 2025. Link
- Sun Pharma. Sun Pharma launches its semaglutide injection under the brand names Noveltreat and Sematrinity in India (Noveltreat, 0.25 to 2.4 mg: "weekly therapy costs, from initiation to the highest dose, range from approximately ₹900 to ₹2,000", so ₹3,600 to ₹8,000 for 4 doses). Press release, 21 March 2026. PDF
- Dr Reddy's Laboratories. Launch of Obeda (semaglutide injection) for type 2 diabetes: 2 mg and 4 mg pens, each "a minimum of 4 weekly doses"; "INR 4,200 per month for both the strengths". Press release filed with the US SEC, 21 March 2026. Link
- BusinessToday. NATCO opens semaglutide market at ₹1,290 (multi-dose vials: ₹1,290 a month for lower strengths, up to ₹1,750 for the highest). 20 March 2026. Link
- Mounjaro KwikPen MRP per pen of 4 doses, as listed by PharmEasy (updated 1 October 2026) and MrMed: 5 mg ₹16,406 (MrMed ₹16,406.25); 7.5 and 10 mg ₹20,625. Eli Lilly and Company India. Pharmacy-listed MRP, 2 listings agree. Checked 5 October 2026.
- Press Information Bureau (Ministry of Finance). Recommendations of the 56th meeting of the GST Council ("Reduction of GST on all other drugs and medicines from 12% to 5%"; changes on goods "implemented with effect from 22 September 2025"). 3 September 2025. PDF
- National Pharmaceutical Pricing Authority (NPPA). Office memorandum F. No. 12(24)/2021/DP/NPPA/Div.II(Vol.II)-Part(1), "Implementation of revision in maximum retail price (MRP) due to reduction in Goods and Service Tax (GST) rates", 13 September 2025, revising the memorandum of 12 September 2025: makers to issue revised price lists "reflecting the revised GST rates and Revised MRP". PDF
- Alkem Laboratories. Press release: semaglutide launch ("pre-filled disposable injection pen, containing four doses for a month, at an affordable price starting INR 1,800"). 21 March 2026. PDF
Last checked 5 Oct 2026 · Next review due Jan 2027 · Report an error
How this guide was made. Written by the GLP Guidebook team from the sources above: published trials, drug labels and named news reports. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write